Mylan NV (MYL)

pos +0.24
Today's Range: 38.79 - 39.04 | MYL Avg Daily Volume: 5,519,200
Last Update: 06/28/17 - 10:06 AM EDT
Volume: 199,889
YTD Performance: 0.73%
Open: $38.80
Previous Close: $38.43
52 Week Range: $37.59 - $67.34
Oustanding Shares: 535,981,661
Market Cap: 20,919,364,229
6-Month Chart
TheStreet Ratings Grade for MYL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 6 5 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 1.91 2.00 1.91
Latest Dividend: 0.00
Latest Dividend Yield: 0.54%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 38.64
Price Earnings Comparisons:
MYL Sector Avg. S&P 500
38.64 22.90 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-7.86% -8.08% -25.39%
Revenue 22.10 0.40 0.11
Net Income -9.20 0.30 0.10
EPS -27.00 0.20 0.05
Earnings for MYL:
Revenue 9.43B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.21 $1.45 $5.25 $5.69
Number of Analysts 5 5 6 6
High Estimate $1.29 $1.61 $5.32 $6.03
Low Estimate $1.12 $1.29 $5.19 $5.35
Prior Year $1.16 $1.38 $4.89 $5.25
Growth Rate (Year over Year) 4.48% 5.07% 7.33% 8.45%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Jun 16, 2017 | 9:26 AM EDT
Cantor Fitzgerald has initiated coverage of Mylan with a "Neutral" rating.
It looks like the stock is trying to rebase again.
Drug companies are the latest targets/beneficiaries.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Prices look set to test key resistance, and this time should see a breakout to the upside.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
Jan 05, 2017 | 7:26 AM EST
MYL was downgraded to Neutral, Citigroup said. $44 price target. Valuation call, as estimates are below consensus.
Even among the losers, buys are scarce.
If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

Columnist Conversations

Warren Buffett's recent purchase of Store Capital Corp. (STOR), a real estate investment trust (REIT), seems t...
One of the big changes in this market in recent years is that all the very simple technical indicators tend to...
Yellen says valuations are rich, Fischer seems inclined to agree. Here comes the market top...
SMH, an etf to be long the semis has support in this 81-ish area. And 78-79 is a short term measured target.&n...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.